In Vitro Efficacy Testing Services for Peritoneum Cancer

We provide robust and sensitive in vitro screening and characterization platforms for accelerating the discovery and screening of potential therapies for Peritoneum Cancer. Our service offers comprehensive analysis of drug efficacy, cytotoxicity, and molecular mechanisms using patient-relevant cellular models and state-of-the-art assays. Key targets and pathways for Peritoneum Cancer, such as cell proliferation, apoptosis, immune checkpoint pathways, and multidrug resistance proteins, are addressed in our testing portfolio. We evaluate critical pathological processes including tumor cell viability, drug resistance, immune modulation, and protein interactions specific to the peritoneal microenvironment.

Our in vitro testing services encompass a diverse array of biochemical, cell-based, and molecular assays designed to elucidate the efficacy, mechanism of action, and safety of investigational compounds. These methods enable precise quantification of cellular responses, protein interactions, gene expression, and pharmacodynamic effects relevant to Peritoneum Cancer. The goal is to deliver actionable data to inform lead optimization and preclinical development.

ATP assay: Measures cellular ATP levels as an indicator of cell viability and metabolic activity, providing insights into cytotoxic effects of compounds.

Biolayer interferometry assay: Detects biomolecular interactions in real time, useful for characterizing binding kinetics of drug candidates to target proteins.

Bioluminescence resonance energy transfer (BRET) assay: Monitors protein-protein interactions and signaling events in live cells via energy transfer between luminescent proteins.

Calcein-AM efflux assay: Assesses the activity of drug efflux pumps to evaluate multidrug resistance in cancer cells.

Cell counting assay (with charcoal-stripped serum-treated): Quantifies cell proliferation under hormone-depleted conditions to study hormone responsiveness.

Cells (effector) transfected with PD1: Used to model immune checkpoint interactions and evaluate immunotherapy candidates targeting PD-1/PD-L1 pathways.

Chemiluminescent assay: Quantifies target molecules or cellular responses using chemiluminescence, enhancing sensitivity for low-abundance analytes.

Competitive binding assay: Measures the ability of compounds to compete with radiolabeled or fluorescent ligands for binding to target receptors.

Daunorubicin accumulation assay: Determines intracellular accumulation of daunorubicin as a marker for drug transport and resistance mechanisms.

Dimerization assay: Evaluates the formation of protein dimers, particularly relevant to signaling pathway activation in cancer biology.

Displacement of [3H]-metribolone: Assesses binding affinities of test compounds to steroid hormone receptors by measuring displacement of radiolabeled ligand.

Displacement of [3H]-mibolerone: Similar to the above, used to evaluate androgen receptor binding and antagonist potential.

Dye assay (MTT): Quantifies cell viability by measuring mitochondrial reduction of MTT to formazan, a standard for cytotoxicity screening.

Dye assay (WST-8): Similar to MTT, WST-8 is a water-soluble dye used for rapid quantification of cell proliferation and viability.

ELISA assay: Detects and quantifies proteins, cytokines, or antibodies in biological samples, enabling measurement of immune response and biomarker expression.

Enzyme immunoassay (EIA): Utilizes enzyme-labeled antibodies to detect specific targets, facilitating sensitive quantification of proteins or small molecules.

Flow cytometry assay: Analyzes cell populations based on size, granularity, and fluorescence, allowing multiparametric assessment of cell death, proliferation, and surface markers.

Fluorescent assay: Employs fluorescence-based detection for quantifying molecular interactions, enzyme activity, or cellular events.

Fluorescent assay (with dihydrotestosterone): Evaluates androgen receptor activity through fluorescent detection in response to dihydrotestosterone stimulation.

Fluorescent polarization assay: Measures changes in fluorescence polarization to study ligand binding and molecular interactions.

Fluorescent-activated cell sorting (FACS) assay: Enables sorting and analysis of specific cell subpopulations based on fluorescent markers.

Gene reporter assay: Monitors gene expression changes by quantifying reporter gene activity, revealing pathway modulation by test compounds.

Hoechst33342 uptake assay: Assesses drug transport and multidrug resistance by quantifying uptake of the fluorescent Hoechst dye.

Homogeneous Time Resolved Fluorescence (HTRF) assay: Combines FRET with time-resolved measurement for sensitive detection of molecular interactions.

Jurkat human T-cell leukemia cells transfected with PD1: Utilized to assess the impact of therapies on T-cell immune checkpoint function.

Jurkat human T-cell leukemia cells transfected with PD1/NFAT: Models T-cell activation and immune checkpoint signaling for immuno-oncology studies.

Jurkat human T-cell leukemia cells transfected with PD1/NFAT/luciferase: Integrates reporter gene expression for sensitive detection of immune-modulatory effects.

Luciferine/luciferase assay: Measures bioluminescence as a readout for cell viability, gene expression, or reporter activity.

Poly(L-glutamate/L-tyrosine) [Poly(E,Y)1-4] as substrate: Used to study enzyme activity or protein interactions involving polyamino acid substrates.

RNA assay: Quantifies gene expression changes at the RNA level, supporting mechanistic studies of drug action.

Radioactivity assay: Detects radiolabeled compounds in binding or uptake studies, offering high sensitivity for target engagement.

Rhodamine accumulation assay: Assesses intracellular accumulation of rhodamine dye to evaluate drug efflux and resistance mechanisms.

Saturation binding assay: Determines binding affinity and receptor density by measuring ligand binding at increasing concentrations.

Surface plasmon resonance assay: Provides real-time kinetic analysis of molecular interactions without labeling, important for drug-target binding characterization.

Transactivation assay: Measures activation of transcription factors or nuclear receptors, revealing pathway-specific drug effects.

p53 peptide as substrate: Used to assess activity of proteins or enzymes interacting with the tumor suppressor p53, relevant for cancer pathways.

We measure a comprehensive set of pharmacological parameters to evaluate compound potency, efficacy, selectivity, and cytotoxicity in our in vitro assays. These parameters, including IC-50, EC-50, CC-50, Kd, and others, are critical for benchmarking candidate molecules and identifying optimal therapeutic windows. Accurate parameter determination supports data-driven decisions in drug development pipelines.

CC-50: The concentration of a compound that reduces cell viability by 50%, crucial for assessing cytotoxicity and safety margins.

EC-50: The concentration required to achieve 50% of the maximal desired biological effect, indicating compound potency.

IC-50: The concentration that inhibits a given biological or biochemical function by 50%, widely used to measure inhibitor effectiveness.

Kd: The equilibrium dissociation constant, representing the affinity between a ligand and its target; lower values indicate stronger binding.

Ki: The inhibition constant, quantifying the binding affinity of an inhibitor for its target enzyme or receptor.

MCC (Minimum Cytotoxic Concentration): The lowest concentration at which cytotoxic effects are observed, important for safety profiling.

MEC (Minimum Effective Concentration): The lowest concentration at which a therapeutic effect is observed, relevant for dose selection.

MIC (Minimum Inhibitory Concentration): The lowest concentration that inhibits visible growth of a target organism or cell population, critical for antimicrobial and anti-cancer screening.

Recommended In Vitro Efficacy Tests

Androgen Receptor

Androgen Receptor (AR) is implicated in Peritoneum Cancer progression and therapy response. Testing AR activity is vital for drug development, enabling identification of effective therapeutics. Our service offers comprehensive AR profiling using assays such as BRET, luciferase, RNA, binding (e.g., [3H]-mibolerone, [3H]-metribolone), gene reporter, and cell viability assays (WST-8, MTT). Key parameters measured include Ki, IC-50, Kd, EC-50, MCC, MIC, MEC, and CC-50, ensuring robust evaluation of candidate compounds.

Angiopoietin 2

Angiopoietin 2 plays a crucial role in peritoneum cancer progression by promoting angiogenesis and tumor vascular remodeling. Testing Angiopoietin 2 is vital for evaluating drug efficacy and disease prognosis. Our service utilizes biolayer interferometry assays to accurately quantify Angiopoietin 2 interactions, providing key binding affinity parameters such as Kd. This enables precise assessment of therapeutic candidates targeting angiogenic pathways in peritoneum cancer drug development.

Atp Binding Cassette Subfamily B Member 1

ATP Binding Cassette Subfamily B Member 1 (ABCB1) plays a key role in multidrug resistance in Peritoneum Cancer by actively effluxing chemotherapeutic agents. ABCB1 testing is crucial to evaluate drug efficacy and resistance mechanisms during drug development. Key methods include Hoechst33342 uptake, Calcein-AM and Daunorubicin accumulation, Rhodamine assays, and RNA analysis. Main parameters assessed are MIC and IC50, providing essential data for optimizing therapeutic strategies.

Atr Checkpoint Kinase

ATR Checkpoint Kinase plays a crucial role in DNA damage response in Peritoneum Cancer, making it a key drug target. Our testing service evaluates ATR inhibitors using chemiluminescent, HTRF, ATP, and radioactivity assays with p53 peptide substrates. Key parameters measured include Ki, MIC, and IC-50, providing essential data for drug efficacy and optimization in Peritoneum Cancer therapy development.

Axl Receptor Tyrosine Kinase

The Axl Receptor Tyrosine Kinase is implicated in peritoneum cancer progression and drug resistance, making it a vital therapeutic target. Our testing service evaluates candidate drugs by measuring Axl kinase activity using Poly(L-glutamate/L-tyrosine) [Poly(E,Y)1-4] as a substrate and ATP-based assays. The primary parameter reported is IC-50, enabling precise assessment of compound potency for peritoneum cancer drug development.

Baculoviral Iap Repeat Containing 2

Baculoviral Iap Repeat Containing 2 (BIRC2) regulates apoptosis and is often upregulated in Peritoneum Cancer, promoting tumor survival. Testing BIRC2 expression or function is crucial for identifying therapeutic targets and assessing drug efficacy. Key methods include qPCR, immunohistochemistry, and Western blotting. Main parameters measured are BIRC2 mRNA/protein levels, localization, and changes in response to candidate drugs.

Cd274 Molecule

The Cd274 molecule (PD-L1) plays a crucial role in immune evasion in Peritoneum Cancer by inhibiting T-cell activation. Testing Cd274 is essential for developing immunotherapies targeting this pathway. Our service utilizes advanced assays—including FACS, chemiluminescent, flow cytometry, ELISA, surface plasmon resonance, biolayer interferometry, luciferase reporter systems (using PD1/NFAT/Jurkat cells), and RNA analysis—to measure key parameters such as MEC, Kd, IC-50, and MIC, ensuring robust drug candidate evaluation.

Cd276 Molecule

The Cd276 molecule, overexpressed in peritoneum cancer, is a promising immunotherapy target. Testing its involvement enables identification of effective drug candidates. Using ELISA and biolayer interferometry assays, we assess key parameters such as binding affinity (Kd) and inhibitory concentration (IC-50), providing critical data for drug development and optimizing therapeutic strategies targeting Cd276 in peritoneum cancer.